Biomea Fusion, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-09-22: Form 8-K; Period of report 2026-09-22; Description 8.01 Other Events; Details 8.01.
- 2026-08-05: Form 8-K; Period of report 2026-08-05; Description 9.01 Financial Statements and Exhibits; Details 9.01.
- 2026-06-11: Form 8-K; Period of report 2026-06-10; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2026-05-11: Form 8-K; Period of report 2026-05-11; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2026-09-22 | 8-K | 2026-09-22 | 8.01 Other Events | 8.01 On September 22, 2026, Biomea Fusion, Inc. (the “Company”) updated the anticipated timing for topline results from the Company’s ongoing Phase I GLP-131 trial for BMF-650 in obese, otherwise healthy volunteers, which are now expected in October 2026. | bmea-20260922.htm |
| 2026-08-05 | 8-K | 2026-08-05 | 9.01 Financial Statements and Exhibits | 9.01 99.1 Press release dated August 5, 2026, furnished herewith. | bmea-20260805.htm |
| 2026-06-11 | 8-K | 2026-06-10 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The proposals set forth below were submitted to the stockholders at the Annual Meeting of Stockholders (the “Annual Meeting”) held on June 10, 2026, with each such proposal described in the Proxy Statement. | d155200d8k.htm |
| 2026-05-11 | 8-K | 2026-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2026, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. | bmea-20260511.htm |
| 2026-04-28 | 8-K | 2026-04-27 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On April 28, 2026, Biomea Fusion, Inc. (the “Company”) hosted a conference call and live webcast to discuss topline data for its Phase 2 COVALENT-112 study. 8.01 On April 27, 2026, the Company reported positive 52-week results from its Phase 2 COVALENT-112 trial evaluating the efficacy, safety, and tolerability of icovamenib in patients with type 1 diabetes (“T1D”). | d142809d8k.htm |
| 2026-03-24 | 8-K | 2026-03-24 | 2.02 Results of Operations and Financial Condition | 2.02 On March 24, 2026, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended and year ended December 31, 2025. | bmea-20260324.htm |
| 2026-02-25 | 8-K | 2026-02-25 | 7.01 Regulation FD Disclosure | 7.01 On February 25, 2026, Biomea Fusion, Inc. (the “Company”) updated its corporate presentation to be used from time to time with investors, analysts and other third parties (the “Corporate Presentation”). | d95198d8k.htm |
| 2026-01-14 | 8-K | 2026-01-14 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On January 14, 2026, Biomea Fusion, Inc. (the “Company”) presented at the 44th Annual J.P. Morgan Healthcare Conference, which took place from January 12-15, 2026 in San Francisco, California. 8.01 On January 14, 2026, the Company updated its corporate presentation to be used from time to time with investors, analysts and other third parties (the “Corporate Presentation”). | d747443d8k.htm |
| 2025-11-04 | 8-K | 2025-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2025, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. | bmea-20251104.htm |
| 2025-10-07 | 8-K | 2025-10-06 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On October 6, 2025, the Company issued a press release announcing the Offering and on October 7, 2025, the Company issued a press release announcing the pricing of the Offering. | d237219d8k.htm |
| 2025-10-06 | 8-K | 2025-10-06 | 8.01 Other Events | 8.01 On October 6, 2025, Biomea Fusion, Inc. (the “Company”) reported new 52-week results from Phase II COVALENT-111 study in Type 2 diabetes. | d79150d8k.htm |
| 2025-08-05 | 8-K | 2025-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2025, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. | bmea-20250805.htm |
| 2025-07-24 | 8-K | 2025-07-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 22, 2025, Bihua Chen informed the Board of Directors (the “Board”) of Biomea Fusion, Inc. (the “Company”) that she is resigning as a member of the Board and as chairperson of the Compensation Committee of the Board and member of the Nominating and Corporate Governance Committee of the Board, effective immediately. | d57486d8k.htm |
| 2025-06-20 | 8-K | 2025-06-17 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d877313d8k.htm |
| 2025-06-18 | 8-K | 2025-06-17 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On June 17, 2025, the Company issued a press release announcing the Offering and on June 17, 2025, the Company issued a press release announcing the pricing of the Offering. | d44604d8k.htm |
| 2025-06-17 | 8-K | 2025-06-17 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On June 17, 2025, Biomea Fusion, Inc. (the “Company”) posted to the “Investors & Media” section of the Company’s website at www.biomeafusion.com an updated corporate presentation (the “Corporate Presentation”). 8.01 On June 17, 2025, the Company reported new preclinical findings from a 28-day weight loss study in obese non-human primates evaluating BMF-650, the Company’s investigational, next-generation oral small molecule Glucagon-like peptide-1 receptor agonist (“GLP-1 RA”) candidate. | d915732d8k.htm |
| 2025-06-13 | 8-K | 2025-06-11 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The proposals set forth below were submitted to the stockholders at the Annual Meeting held on June 11, 2025, with each such proposal described in the Proxy Statement. | d89465d8k.htm |
| 2025-05-05 | 8-K | 2025-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2025, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. | bmea-20250505.htm |
| 2025-03-31 | 8-K | 2025-03-31 | 2.02 Results of Operations and Financial Condition | 2.02 On March 31, 2025, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended and year ended December 31, 2024. | bmea-20250331.htm |
| 2025-03-27 | 8-K | 2025-03-25 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 3.01 On March 27, 2025, Biomea Fusion, Inc. (the “Company”) notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the audit committee requirement under Nasdaq Listing Rule 5605(c)(2)(A) due to the Company having only two members on its audit committee (the “Audit Committee”) of its Board of Directors of the Company (the “Board”) solely due to a vacancy resulting from Michael (Mick) J.M. Hitchcock, Ph.D.’s resignation from the Audit Committee in connection with his appointment as interim Chief Executive Officer of the Company effective March 25, 2025. 5.02 The employment of Thomas Butler as Chief Executive Officer of the Company ended on March 25, 2025 (the “Effective Date”). 7.01 On March 25, 2025, the Company issued a press release announcing the leadership changes described above. | d945354d8k.htm |
| 2025-02-28 | 8-K | 2025-02-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 24, 2025, Franco Valle resigned as the Chief Financial Officer (principal financial officer and principal accounting officer) of Biomea Fusion, Inc. (the “Company”), effective March 7, 2025. | d893104d8k.htm |
| 2025-01-15 | 8-K | 2025-01-13 | 8.01 Other Events | 8.01 On January 13, 2025, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “Biomea Fusion to Become a Diabetes & Obesity Medicines Company.” The information described in the press release was presented by the Company in an updated corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference, which took place from January 13-16, 2025 in San Francisco, California. | d830016d8k.htm |
| 2024-12-20 | 8-K | 2024-12-17 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On December 17, 2024, Biomea Fusion, Inc. (the “Company”) issued a press release announcing topline data from the Phase II portion of COVALENT-111, the Company’s clinical trial of its lead product candidate, icovamenib, in type 2 diabetes. 8.01 On December 17, 2024, the Company reported positive topline results from its ongoing Phase II COVALENT-111 Study in patients with type 2 diabetes (“T2D”). | d827448d8k.htm |
| 2024-10-31 | 8-K | 2024-10-30 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 Biomea Fusion, Inc. (the “Company”) hosted a conference call and live webcast to discuss the preclinical data on October 30, 2024 at 4:30 p.m. 8.01 On October 30, 2024, the Company issued a press release titled, “Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate.” A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.2 and is incorporated herein by reference. | d850084d8k.htm |
| 2024-10-29 | 8-K | 2024-10-29 | 2.02 Results of Operations and Financial Condition | 2.02 On October 29, 2024, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2024. | bmea-20241029.htm |
| 2024-09-27 | 8-K | 2024-09-26 | 8.01 Other Events | 8.01 On September 26, 2024, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials.” A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. | d310466d8k.htm |
| 2024-07-31 | 8-K | 2024-07-31 | 2.02 Results of Operations and Financial Condition | 2.02 On July 31, 2024, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2024. | bmea-20240731.htm |
| 2024-06-12 | 8-K | 2024-06-12 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The proposals set forth below were submitted to the stockholders at the Annual Meeting held on June 12, 2024, with each such proposal described in the Proxy Statement. | d851376d8k.htm |
| 2024-06-07 | 8-K | 2024-06-06 | 8.01 Other Events | 8.01 On June 6, 2024, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold.” A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. | d94044d8k.htm |
| 2024-05-02 | 8-K | 2024-05-02 | 2.02 Results of Operations and Financial Condition | 2.02 On May 2, 2024, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024. | bmea-20240502.htm |
| 2024-04-01 | 8-K | 2024-04-01 | 8.01 Other Events | 8.01 On April 1, 2024, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219.” A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. | d765540d8k.htm |
| 2024-04-01 | 8-K | 2024-04-01 | 2.02 Results of Operations and Financial Condition | 2.02 On April 1, 2024, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended and year ended December 31, 2023. | bmea-20240401.htm |
| 2024-03-07 | 8-K | 2024-03-06 | 8.01 Other Events | 8.01 On March 6, 2024, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function.” The information described in the press release was also presented in three poster presentations at the 17th International Conference on Advanced Technologies & Treatments for Diabetes, which is taking place March 6-9, 2024 in Florence, Italy. | d802391d8k.htm |
| 2024-01-10 | 8-K | 2024-01-09 | 8.01 Other Events | 8.01 On January 9, 2024, Biomea Fusion, Inc., or the Company, presented a business update at the 42nd Annual J.P. Morgan Healthcare Conference. | d612982d8k.htm |
| 2023-10-30 | 8-K | 2023-10-30 | 2.02 Results of Operations and Financial Condition | 2.02 On October 30, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023. | bmea-20231030.htm |
| 2023-07-31 | 8-K | 2023-07-31 | 2.02 Results of Operations and Financial Condition | 2.02 On July 31, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023. | bmea-20230731.htm |
| 2023-07-25 | 8-K | 2023-07-24 | 8.01 Other Events | 8.01 On July 24, 2023, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population.” A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. | d434383d8k.htm |
| 2023-06-15 | 8-K | 2023-06-14 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The proposals set forth below were submitted to the stockholders at the Annual Meeting held on June 14, 2023, with each such proposal described in the Proxy Statement. | d516349d8k.htm |
| 2023-05-02 | 8-K | 2023-05-01 | 8.01 Other Events | 8.01 On May 1, 2023, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia.” A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference. | d851586d8k.htm |
| 2023-05-02 | 8-K | 2023-05-02 | 2.02 Results of Operations and Financial Condition | 2.02 On May 2, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2023. | bmea-20230502.htm |
| 2023-04-03 | 8-K | 2023-03-29 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On March 29, 2023, the Company issued a press release announcing the Offering and on March 29, 2023, the Company issued a press release announcing the pricing of the Offering. | d486927d8k.htm |
| 2023-03-28 | 8-K | 2023-03-28 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On March 28, 2023, Biomea Fusion, Inc. (the “Company”) issued a press release announcing initial clinical data from the Phase II portion of COVALENT-111, the Company’s clinical trial of its lead product candidate, BMF-219, in type 2 diabetes. 8.01 On March 28, 2023, the Company reported topline initial clinical data from the Phase 2 portion of COVALENT-111. | d311150d8k.htm |
| 2023-03-28 | 8-K | 2023-03-28 | 2.02 Results of Operations and Financial Condition | 2.02 On March 28, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended and year ended December 31, 2022. | bmea-20230328.htm |
| 2023-01-12 | 8-K | 2023-01-09 | 8.01 Other Events | 8.01 On January 9, 2023, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones.” The information described in the press release was presented by the Company in an updated corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference, which took place from January 9-12, 2023 in San Francisco, California. | d417295d8k.htm |
| 2022-12-16 | 8-K | 2022-12-14 | 8.01 Other Events | 8.01 On December 14, 2022, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes.” A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference. | d426454d8k.htm |
| 2022-12-13 | 8-K | 2022-12-12 | 8.01 Other Events | 8.01 On December 12, 2022, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date.” The information described in the press release was also presented in a presentation at the 64th American Society of Hematology (ASH) Annual Meeting, which took place December 10-13, 2022 in New Orleans, Louisiana. | d424536d8k.htm |
| 2022-11-25 | 8-K | 2022-11-25 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d721850d8k.htm |
| 2022-11-07 | 8-K | 2022-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2022, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022. | bmea-20221107.htm |
| 2022-11-01 | 8-K | 2022-10-31 | 8.01 Other Events | 8.01 On October 31, 2022, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219.” A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference. | d350423d8k.htm |
| 2022-10-18 | 8-K | 2022-10-14 | 8.01 Other Events | 8.01 On October 14, 2022, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “BMF-219 Enters the Clinic for KRAS Solid Tumors.” A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference. | d403732d8k.htm |
| 2022-09-23 | 8-K | 2022-09-22 | 8.01 Other Events | 8.01 On September 22, 2022, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes.” The information described in the press release was also presented in a presentation at the 58th European Association for the Study of Diabetes (EASD) Annual Meeting, which is taking place September 19-23, 2022 in Stockholm, Sweden. | d397871d8k.htm |
| 2022-09-22 | 8-K | 2022-09-20 | 8.01 Other Events | 8.01 On September 20, 2022, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes.” The information described in the press release was also presented in a presentation at the 58th European Association for the Study of Diabetes (EASD) Annual Meeting, which is taking place September 19-23, 2022 in Stockholm, Sweden. | d376137d8k.htm |
| 2022-09-09 | 8-K | 2022-09-07 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. | d393975d8k.htm |
| 2022-08-29 | 8-K | 2022-08-26 | 8.01 Other Events | 8.01 On August 26, 2022, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting.” The information described in the press release was also presented in two poster presentations at the 19th International Myeloma Society (IMS) Annual Meeting, which took place August 25-27, 2022 in Los Angeles, California. | d387782d8k.htm |
| 2022-08-01 | 8-K | 2022-08-01 | 2.02 Results of Operations and Financial Condition | 2.02 On August 1, 2022, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2022. | bmea-20220801.htm |
| 2022-06-23 | 8-K | 2022-06-22 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The proposals set forth below were submitted to the stockholders at the Annual Meeting held on June 22, 2022, with each such proposal described in the Proxy Statement. | d374258d8k.htm |
| 2022-06-06 | 8-K | 2022-06-04 | 8.01 Other Events | 8.01 On June 4, 2022, Biomea Fusion, Inc. (the “Company”) presented preclinical data on its product candidate, BMF-219, in chronic lymphocytic leukemia tumor models at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. | d328908d8k.htm |
| 2022-05-16 | 8-K | 2022-05-16 | 2.02 Results of Operations and Financial Condition | 2.02 On May 16, 2022, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2022. | bmea-20220516.htm |
| 2022-04-22 | 8-K | 2022-04-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 19, 2022, the Compensation Committee of the Board of Directors of Biomea Fusion, Inc. (the “Company”) approved amendments to the Company’s Change in Control and Severance Agreements (the “Amendments”) with each of Thomas Butler, the Company’s Chief Executive Officer; Ramses Erdtmann, the Company’s President and Chief Operating Officer; and Franco Valle, the Company’s Chief Financial Officer (collectively, the “NEOs”). | d142250d8k.htm |
| 2022-04-08 | 8-K | 2022-04-08 | 8.01 Other Events | 8.01 On April 8, 2022, Biomea Fusion, Inc. (the “Company”) issued a press release titled, “Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting.” The information described in the press release is also being presented in poster presentations at the American Association for Cancer Research (AACR) 2022 Annual Meeting on April 12, 2022. | d291903d8k.htm |
| 2022-02-28 | 8-K | 2022-02-28 | 2.02 Results of Operations and Financial Condition | 2.02 On February 28, 2022, Biomea Fusion, Inc. issued a press release announcing its financial results for the year ended December 31, 2021. | bmea-8k_20220228.htm |
| 2022-01-12 | 8-K | 2022-01-12 | 7.01 Regulation FD Disclosure | 7.01 Biomea Fusion, Inc. (the “Company”) from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. | d279073d8k.htm |
| 2021-11-15 | 8-K | 2021-11-11 | 7.01 Regulation FD Disclosure | 7.01 Biomea Fusion, Inc. (the “Company”) from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. | d243953d8k.htm |
| 2021-11-03 | 8-K | 2021-11-03 | 2.02 Results of Operations and Financial Condition | 2.02 On November 3, 2021, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2021. | bmea-8k_20211103.htm |
| 2021-09-17 | 8-K | 2021-09-16 | 8.01 Other Events | 8.01 On September 16, 2021, Biomea Fusion, Inc. (the “Company”) announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application to begin a Phase 1 trial of BMF-219, a selective irreversible menin inhibitor, in adult patients with relapsed or refractory acute leukemia, including those with an MLL/KM2TA gene rearrangement or NPM1 mutation. | d201987d8k.htm |
| 2021-08-11 | 8-K | 2021-08-11 | 2.02 Results of Operations and Financial Condition | 2.02 On August 11, 2021, Biomea Fusion, Inc. issued a press release announcing its financial results as of and for the quarter ended June 30, 2021. | bmea-8k_20210811.htm |
| 2021-07-19 | 8-K | 2021-07-19 | 7.01 Regulation FD Disclosure | 7.01 Biomea Fusion, Inc. (the “Company”) from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. | d157336d8k.htm |
| 2021-07-12 | 8-K/A | 2021-07-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 28, 2021, Biomea Fusion, Inc. Biomea Fusion, Inc. (“Biomea Fusion” or the “Company”) announced that Franco Valle, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will commence employment with the Company on July 26, 2021, as previously reported pursuant to a Current Report on Form 8-K filed by the Company on June 29, 2021. | d134421d8ka.htm |
| 2021-07-09 | 8-K | 2021-07-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 28, 2021, Biomea Fusion, Inc. Biomea Fusion, Inc. (“Biomea Fusion” or the “Company”) announced that Franco Valle, Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer, will commence employment with the Company on July 26, 2021, as previously reported pursuant to a Current Report on Form 8-K filed by the Company on June 29, 2021. | d189045d8k.htm |
| 2021-06-29 | 8-K | 2021-06-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 28, 2021, Biomea Fusion, Inc. (the “Company”) announced the appointment of Franco Valle to the position of Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the Company effective as of July 26, 2021. | d169850d8k.htm |
| 2021-06-17 | 8-K | 2021-06-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 11, 2021, Sumita Ray, J.D. was appointed to the Board of Directors (the “Board”) of Biomea Fusion, Inc. (the “Company”), effective June 16, 2021, as a Class I director, with an initial term expiring at the Company’s 2022 annual meeting of stockholders, filling a vacancy. | d169183d8k.htm |
| 2021-05-27 | 8-K | 2021-05-27 | 2.02 Results of Operations and Financial Condition | 2.02 On May 27, 2021, Biomea Fusion, Inc. issued a press release announcing its financial results as of and for the quarter ended March 31, 2021. | bmea-8k_20210527.htm |
| 2021-04-20 | 8-K | 2021-04-20 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 5.03 On April 20, 2021, Biomea Fusion, Inc.’s (the “Company”) amended and restated certificate of incorporation (the “Certificate of Incorporation”) was filed with the Secretary of State of the State of Delaware and its amended and restated bylaws (the “Bylaws”) became effective in connection with the closing of the initial public offering of shares of the Company’s common stock. 8.01 On April 20, 2021, the Company closed its initial public offering of 9,000,000 shares of its common stock at a price to the public of $17.00 per share. | d119708d8k.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |